Humana Inc. $HUM Shares Bought by Swiss National Bank

Swiss National Bank lifted its stake in shares of Humana Inc. (NYSE:HUM) by 7.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 365,400 shares of the insurance provider’s stock after acquiring an additional 25,700 shares during the period. Swiss National Bank’s holdings in Humana were worth $89,333,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Cary Street Partners Investment Advisory LLC raised its position in shares of Humana by 63.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after buying an additional 46 shares during the last quarter. Applied Finance Capital Management LLC boosted its holdings in shares of Humana by 1.7% during the first quarter. Applied Finance Capital Management LLC now owns 2,943 shares of the insurance provider’s stock worth $779,000 after purchasing an additional 48 shares during the last quarter. Blue Trust Inc. increased its stake in Humana by 3.6% in the second quarter. Blue Trust Inc. now owns 1,367 shares of the insurance provider’s stock valued at $334,000 after purchasing an additional 48 shares during the last quarter. Atlas Brown Inc. lifted its position in Humana by 0.9% during the second quarter. Atlas Brown Inc. now owns 6,369 shares of the insurance provider’s stock worth $1,557,000 after buying an additional 54 shares during the period. Finally, Townsquare Capital LLC boosted its stake in Humana by 2.8% in the 1st quarter. Townsquare Capital LLC now owns 2,255 shares of the insurance provider’s stock worth $597,000 after buying an additional 61 shares during the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Performance

Humana stock opened at $226.78 on Friday. Humana Inc. has a 12-month low of $206.87 and a 12-month high of $315.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The company has a market capitalization of $27.28 billion, a price-to-earnings ratio of 17.40, a price-to-earnings-growth ratio of 1.71 and a beta of 0.42. The firm’s fifty day moving average price is $265.77 and its 200 day moving average price is $257.08.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, November 5th. The insurance provider reported $3.24 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.29. Humana had a return on equity of 13.67% and a net margin of 1.28%.The firm had revenue of $32.65 billion during the quarter, compared to the consensus estimate of $31.99 billion. During the same quarter in the prior year, the business posted $4.16 earnings per share. Humana’s revenue for the quarter was up 11.1% on a year-over-year basis. On average, research analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be given a $0.885 dividend. The ex-dividend date is Friday, December 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.6%. Humana’s dividend payout ratio (DPR) is presently 33.18%.

Analyst Ratings Changes

HUM has been the subject of a number of research analyst reports. Piper Sandler dropped their price objective on shares of Humana from $288.00 to $272.00 and set a “neutral” rating for the company in a research note on Thursday, July 31st. Wolfe Research lowered their target price on shares of Humana from $313.00 to $300.00 and set an “outperform” rating for the company in a report on Thursday. Wells Fargo & Company upped their price target on shares of Humana from $344.00 to $347.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 7th. Morgan Stanley dropped their price objective on Humana from $290.00 to $277.00 and set an “equal weight” rating for the company in a report on Thursday, July 31st. Finally, Truist Financial reduced their price objective on Humana from $300.00 to $285.00 and set a “hold” rating on the stock in a research note on Monday, November 10th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $297.67.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.